News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Neuren Pharmaceuticals Limited Provides Clinical Trials Update
May 11, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Neuren Pharmaceuticals (ASX: NEU) today announced details on the status of its lead compounds, Glypromate® and NNZ-2566. Following is a summary of the current status of the trials. Neuren will provide further updates as the trials progress.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
Phase 3
Australia
MORE ON THIS TOPIC
Drug Development
India’s life sciences sector at turning point for innovation: Report
July 17, 2026
·
2 min read
·
Angela Gabriel
IPO
2026 IPO stock tracker: How newly public biotechs are performing
July 17, 2026
·
1 min read
·
Gabrielle Masson
Business
GSK culls cough program for drug at the heart of $2B Bellus bet after Phase 3 fail
July 17, 2026
·
1 min read
·
Tristan Manalac
Cardiovascular disease
Insmed moves closer to $6B opportunity as PAH drug shows long-term durability
July 17, 2026
·
2 min read
·
Tristan Manalac
